pharmaphorum
@pharmaphorum.bsky.social
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.
pharmaphorum.com/news/hengrui...
pharmaphorum.com/news/hengrui...
January 8, 2026 at 12:52 PM
#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.
pharmaphorum.com/news/hengrui...
pharmaphorum.com/news/hengrui...
Eight digital health technologies (#DHTs) designed to support people with #asthma can be used by the #NHS in England while additional evidence of their benefits is gathered.
pharmaphorum.com/news/nice-en...
pharmaphorum.com/news/nice-en...
January 7, 2026 at 12:39 PM
Eight digital health technologies (#DHTs) designed to support people with #asthma can be used by the #NHS in England while additional evidence of their benefits is gathered.
pharmaphorum.com/news/nice-en...
pharmaphorum.com/news/nice-en...
#GSK's antisense-based drug for chronic #hepatitisB (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.
pharmaphorum.com/news/gsk-pre...
pharmaphorum.com/news/gsk-pre...
January 7, 2026 at 10:53 AM
#GSK's antisense-based drug for chronic #hepatitisB (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.
pharmaphorum.com/news/gsk-pre...
pharmaphorum.com/news/gsk-pre...
The #CDC has upended the #childhoodvaccination schedule, cutting the number of recommended #immunisations in a move that the #Trump administration says brings the US into line with the practice in Denmark.
pharmaphorum.com/news/cdc-cut...
pharmaphorum.com/news/cdc-cut...
January 6, 2026 at 1:39 PM
The #CDC has upended the #childhoodvaccination schedule, cutting the number of recommended #immunisations in a move that the #Trump administration says brings the US into line with the practice in Denmark.
pharmaphorum.com/news/cdc-cut...
pharmaphorum.com/news/cdc-cut...
US biotech #AktisOncology has filed IPO documents with the Securities and Exchange Commission (#SEC), in what could be the first #biotech listing on the #Nasdaq in 2026.
pharmaphorum.com/news/aktis-o...
pharmaphorum.com/news/aktis-o...
January 5, 2026 at 2:28 PM
US biotech #AktisOncology has filed IPO documents with the Securities and Exchange Commission (#SEC), in what could be the first #biotech listing on the #Nasdaq in 2026.
pharmaphorum.com/news/aktis-o...
pharmaphorum.com/news/aktis-o...
#NovoNordisk has been handed a crucial legal win by #China's Supreme Court, which has upheld the company's #patent protection on #GLP1 agonist #semaglutide used for #diabetes and #weightloss.
pharmaphorum.com/news/china-d...
pharmaphorum.com/news/china-d...
January 2, 2026 at 2:20 PM
#NovoNordisk has been handed a crucial legal win by #China's Supreme Court, which has upheld the company's #patent protection on #GLP1 agonist #semaglutide used for #diabetes and #weightloss.
pharmaphorum.com/news/china-d...
pharmaphorum.com/news/china-d...
Denmark's #Genmab has decided not to continue the development of a drug for #cancer, acasunlimab, which had reached phase 3 testing, after a #review of its medicines #pipeline.
pharmaphorum.com/news/genmab-...
pharmaphorum.com/news/genmab-...
January 2, 2026 at 11:21 AM
Denmark's #Genmab has decided not to continue the development of a drug for #cancer, acasunlimab, which had reached phase 3 testing, after a #review of its medicines #pipeline.
pharmaphorum.com/news/genmab-...
pharmaphorum.com/news/genmab-...
One criticism of injectable #weightloss drugs is that people tend to put the pounds back on after they stop taking them. Could a new generation of #oraltherapies address that issue?
buff.ly/YWzVN7W
buff.ly/YWzVN7W
December 18, 2025 at 5:02 PM
One criticism of injectable #weightloss drugs is that people tend to put the pounds back on after they stop taking them. Could a new generation of #oraltherapies address that issue?
buff.ly/YWzVN7W
buff.ly/YWzVN7W
Armed with positive results in two phase 3 trials, #Takeda intends to file for approval of its oral #psoriasis therapy zasocitinib in the #US and other countries next year, with #BristolMyersSquibb's Sotyktu in its sights.
buff.ly/uIoOyTt
buff.ly/uIoOyTt
December 18, 2025 at 2:00 PM
Armed with positive results in two phase 3 trials, #Takeda intends to file for approval of its oral #psoriasis therapy zasocitinib in the #US and other countries next year, with #BristolMyersSquibb's Sotyktu in its sights.
buff.ly/uIoOyTt
buff.ly/uIoOyTt
The next two discretionary #priorityvouchers to be awarded by the #FDA are reported to be heading for two #MSD candidates with blockbuster potential.
pharmaphorum.com/news/msd-cla...
pharmaphorum.com/news/msd-cla...
December 18, 2025 at 12:31 PM
The next two discretionary #priorityvouchers to be awarded by the #FDA are reported to be heading for two #MSD candidates with blockbuster potential.
pharmaphorum.com/news/msd-cla...
pharmaphorum.com/news/msd-cla...
Regulators in the #UK and #US are the first to approve #GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe #asthma that has been billed as a major new product for the drugmaker.
pharmaphorum.com/news/uk-us-a...
pharmaphorum.com/news/uk-us-a...
December 17, 2025 at 11:31 AM
Regulators in the #UK and #US are the first to approve #GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe #asthma that has been billed as a major new product for the drugmaker.
pharmaphorum.com/news/uk-us-a...
pharmaphorum.com/news/uk-us-a...
#Shares in #Sanofi were sliding today after a double dose of bad news for its oral #BTKinhibitor tolebrutinib, in development as a therapy for #multiplesclerosis (MS).
buff.ly/zKhsMA8
buff.ly/zKhsMA8
December 15, 2025 at 2:30 PM
#Shares in #Sanofi were sliding today after a double dose of bad news for its oral #BTKinhibitor tolebrutinib, in development as a therapy for #multiplesclerosis (MS).
buff.ly/zKhsMA8
buff.ly/zKhsMA8
Among seven new medicines recommended for approval by the #EMA's human medicine advisory committee at its latest meeting is #GSK's depemokimab, a long-acting anti-IL-5 antibody for severe #asthma and an #inflammatorycondition that causes nasal polyps.
pharmaphorum.com/news/gsk-clo...
pharmaphorum.com/news/gsk-clo...
December 15, 2025 at 1:25 PM
Among seven new medicines recommended for approval by the #EMA's human medicine advisory committee at its latest meeting is #GSK's depemokimab, a long-acting anti-IL-5 antibody for severe #asthma and an #inflammatorycondition that causes nasal polyps.
pharmaphorum.com/news/gsk-clo...
pharmaphorum.com/news/gsk-clo...
#EliLilly has ramped up the competition in #weightloss therapies by reporting the first pivotal data with its triple therapy #retatrutide, showing average weight losses of up to 28.7% in its first phase 3 readout.
buff.ly/6sdgkKS
buff.ly/6sdgkKS
December 11, 2025 at 5:00 PM
#EliLilly has ramped up the competition in #weightloss therapies by reporting the first pivotal data with its triple therapy #retatrutide, showing average weight losses of up to 28.7% in its first phase 3 readout.
buff.ly/6sdgkKS
buff.ly/6sdgkKS
#Roche has revealed the data that has it excited about oral #SERD giredestrant in early-stage #breastcancer, which could put the drug on course to add to the options for #adjuvanttherapy.
pharmaphorum.com/news/roche-d...
pharmaphorum.com/news/roche-d...
December 11, 2025 at 12:49 PM
#Roche has revealed the data that has it excited about oral #SERD giredestrant in early-stage #breastcancer, which could put the drug on course to add to the options for #adjuvanttherapy.
pharmaphorum.com/news/roche-d...
pharmaphorum.com/news/roche-d...
After pushing for restrictions on #vaccines for COVID-19 and hepatitis B, the #Trump administration seems to be turning its attention to recently approved shots that protect #infants against #respiratorysyncytialvirus (RSV).
buff.ly/doGx6nP
buff.ly/doGx6nP
December 10, 2025 at 2:30 PM
After pushing for restrictions on #vaccines for COVID-19 and hepatitis B, the #Trump administration seems to be turning its attention to recently approved shots that protect #infants against #respiratorysyncytialvirus (RSV).
buff.ly/doGx6nP
buff.ly/doGx6nP
The #FDA is rolling out a pilot programme that could make it easier to bring #digitalhealth technologies (DHTs) for #chronicdiseases to market more quickly and easily.
buff.ly/q6t9gpb
buff.ly/q6t9gpb
December 8, 2025 at 12:30 PM
The #FDA is rolling out a pilot programme that could make it easier to bring #digitalhealth technologies (DHTs) for #chronicdiseases to market more quickly and easily.
buff.ly/q6t9gpb
buff.ly/q6t9gpb
#ProtegoBiopharma is poised to start pivotal trials of its amyloid light-chain (AL) #amyloidosis drug candidate, thanks to a $130 million second-round #financing.
pharmaphorum.com/news/protego...
pharmaphorum.com/news/protego...
December 5, 2025 at 1:22 PM
#ProtegoBiopharma is poised to start pivotal trials of its amyloid light-chain (AL) #amyloidosis drug candidate, thanks to a $130 million second-round #financing.
pharmaphorum.com/news/protego...
pharmaphorum.com/news/protego...
A #survey of frontline #NHSworkers has found that almost two-thirds (61%) feel they are unprepared for the #digitaltransformation plans laid out in the government's new #10YearPlan for the NHS.
buff.ly/FOM3tTe
buff.ly/FOM3tTe
December 4, 2025 at 3:00 PM
A #survey of frontline #NHSworkers has found that almost two-thirds (61%) feel they are unprepared for the #digitaltransformation plans laid out in the government's new #10YearPlan for the NHS.
buff.ly/FOM3tTe
buff.ly/FOM3tTe
#Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for #Alportsyndrome, a rare, genetic disease that leads to #chronickidneydisease (CKD).
pharmaphorum.com/news/bayer-t...
pharmaphorum.com/news/bayer-t...
December 4, 2025 at 10:40 AM
#Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for #Alportsyndrome, a rare, genetic disease that leads to #chronickidneydisease (CKD).
pharmaphorum.com/news/bayer-t...
pharmaphorum.com/news/bayer-t...
A US #appealscourt has reversed a 2023 decision that ordered #DaiichiSankyo to pay royalties on sales of its antibody-drug conjugate (#ADC) Enhertu to #Seagen, now part of #Pfizer.
buff.ly/AWM9US3
buff.ly/AWM9US3
December 3, 2025 at 3:00 PM
A US #appealscourt has reversed a 2023 decision that ordered #DaiichiSankyo to pay royalties on sales of its antibody-drug conjugate (#ADC) Enhertu to #Seagen, now part of #Pfizer.
buff.ly/AWM9US3
buff.ly/AWM9US3
Long-serving #FDA figure #RichardPazdur has filed papers to #retire, shortly after being appointed to lead the agency's Center for Drug Evaluation and Research (#CDER).
pharmaphorum.com/news/pazdur-...
pharmaphorum.com/news/pazdur-...
December 3, 2025 at 11:26 AM
Long-serving #FDA figure #RichardPazdur has filed papers to #retire, shortly after being appointed to lead the agency's Center for Drug Evaluation and Research (#CDER).
pharmaphorum.com/news/pazdur-...
pharmaphorum.com/news/pazdur-...
The #EMA has started a review of a regimen based on #Pfizer and #Astellas' Padcev and #MSD's Keytruda that has been described as a game-changer in the treatment of muscle-invasive #bladdercancer (MIBC).
buff.ly/h9f0kfX
buff.ly/h9f0kfX
December 1, 2025 at 4:00 PM
The #EMA has started a review of a regimen based on #Pfizer and #Astellas' Padcev and #MSD's Keytruda that has been described as a game-changer in the treatment of muscle-invasive #bladdercancer (MIBC).
buff.ly/h9f0kfX
buff.ly/h9f0kfX
Reports have emerged that #VinayPrasad, head of the FDA's Center for Biologics Evaluation and Research (#CBER), is planning to tighten up the regulations surrounding #vaccines after concluding that #COVID19 shots resulted in the #deaths of 10 children.
pharmaphorum.com/news/fda-abo...
pharmaphorum.com/news/fda-abo...
December 1, 2025 at 12:51 PM
Reports have emerged that #VinayPrasad, head of the FDA's Center for Biologics Evaluation and Research (#CBER), is planning to tighten up the regulations surrounding #vaccines after concluding that #COVID19 shots resulted in the #deaths of 10 children.
pharmaphorum.com/news/fda-abo...
pharmaphorum.com/news/fda-abo...
#InnoventBiologics has picked up approval in #China for Pecondle, its anti-IL-23p19 antibody, as a treatment for moderate-to-severe plaque #psoriasis in adults.
pharmaphorum.com/news/innoven...
pharmaphorum.com/news/innoven...
November 28, 2025 at 2:47 PM
#InnoventBiologics has picked up approval in #China for Pecondle, its anti-IL-23p19 antibody, as a treatment for moderate-to-severe plaque #psoriasis in adults.
pharmaphorum.com/news/innoven...
pharmaphorum.com/news/innoven...